ACTIVE

Hyloris Developments

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-5,3 M €

+9.6% YoY

Revenue

5,1 M €

Equity

17,9 M €

+456.8% YoY

Workforce

12,2 ETP

+11.9% YoY

What does Hyloris Developments do?

Hyloris Developments is a Public limited company incorporated in 2013. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Liège. It employs on average 12,2 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0542.737.368

Incorporation

05/12/2013

Legal form

Public limited company

Registered office

Boulevard de Patience et Beaujonc 3 box 1
4000 Liège · WallonieSee on map

Contributed capital

29 070 737,00 €

Latest accounts

31/12/2025

Average workforce

12,2 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 47730Dispensing chemist in specialised stores 47730Dispensing chemist in specialised stores 47730Dispensing chemist in specialised stores 47730Dispensing chemist in specialised stores

Joint committees (1)

Signals

Solid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 12 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014
Income statement
Revenue	5,1 M €		–		–		–		–		–		–		–		–		–		–		–
EBITDA	4 M €	+42.7%	2,8 M €	+1350%	-227 k €	-385%	79,7 k €	-96.1%	2 M €	+377%	-738,9 k €	-64.3%	-449,8 k €	-276%	255,3 k €	+172%	-355,6 k €	-44.5%	-246,2 k €	-862%	32,3 k €	+137%	-87 k €
Operating result	-5,5 M €	+7.6%	-6 M €	+49.3%	-11,8 M €	-39.0%	-8,5 M €	-270%	-2,3 M €	+19.2%	-2,8 M €	+24.6%	-3,8 M €	-1890%	210,3 k €	+141%	-510 k €	-75.7%	-290,2 k €	-10779%	-2,7 k €	+97.8%	-123,8 k €
Net result	-5,3 M €	+9.6%	-5,8 M €	+46.1%	-10,9 M €	-12.5%	-9,6 M €	-273%	-2,6 M €	+11.8%	-2,9 M €	+28.7%	-4,1 M €	-1156%	-327,6 k €	+37.4%	-523,4 k €	-34.3%	-389,6 k €	-235%	-116,4 k €	+31.0%	-168,7 k €
Balance sheet
Equity	17,9 M €	+457%	3,2 M €	-64.5%	9,1 M €	-54.5%	19,9 M €	+1376%	1,3 M €	-44.6%	2,4 M €	+153%	-4,6 M €	-790%	-520,5 k €	+54.1%	-1,1 M €	-85.8%	-609,7 k €	-177%	-220,2 k €	-112%	-103,7 k €
Total assets	20,6 M €	+104%	10,1 M €	-31.7%	14,8 M €	-36.3%	23,2 M €	+84.6%	12,6 M €	+48.9%	8,4 M €	+14.7%	7,3 M €	-34.0%	11,1 M €	+42.8%	7,8 M €	+118%	3,6 M €	+267%	974,3 k €	+64.7%	591,4 k €
Cash	1,6 M €	+344%	366,2 k €	-2.3%	375 k €	-94.2%	6,5 M €	+274%	1,7 M €	+248%	500 k €	+561%	75,6 k €	-78.0%	343,4 k €	+186%	119,9 k €	-13.2%	138,2 k €	-40.2%	231,1 k €	+513%	37,7 k €
Debts	2,7 M €	-61.2%	6,9 M €	+60.4%	4,3 M €	+212%	1,4 M €	-85.4%	9,4 M €	+105%	4,6 M €	-58.4%	11,1 M €	-0.3%	11,1 M €	+28.3%	8,6 M €	+111%	4,1 M €	+254%	1,2 M €	+68.0%	686,3 k €
Other
Workforce	12,2 ETP	+11.9%	10,9 ETP	+2.8%	10,6 ETP	+19.1%	8,9 ETP	+32.8%	6,7 ETP	+28.8%	5,2 ETP	+23.8%	4,2 ETP	+23.5%	3,4 ETP	+70.0%	2,0 ETP	+17.6%	1,7 ETP	+183%	0,6 ETP		–

Estimate

Indicative valuation

As an indication, this company is worth

between 10 M€ and 25 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 14 ended

Active mandates

Jacobsen Management

Director · since 20 avril 2020 · until 09 juin 2026 · 0736.534.955

Represented by Thomas Jacobsen

Active

SVR Management

Managing director · since 20 avril 2020 · until 09 juin 2026 · 0552.806.859

Represented by Van Rompay Stijn

Active

Ended mandates

Jacobsen Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0736.534.955

Ended

SVR Management

Director · since 20 avril 2020 · until 14 juin 2020 · 0552.806.859

Represented by Stijn Van Rompay

Ended

SVR Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Van Rompay Stijn

Ended

SVR Management

Managing director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Van Rompay Stijn

Ended

At this address

Other companies at this address

Company	CBE no.
Abscint● Active	0749.828.410
AMPACIMON● Active	0827.990.317
Amyl Therapeutics● Active	0758.775.372
BECARV● Bankrupt	0840.777.885
BE.SPINE● Active	1013.110.857
CEFALY Technology● Active	0870.578.661
DERMAX● Active	0667.730.677
DIANOSIC● Active	1034.558.646
DW Cefaly Holding● Active	0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active	1023.778.481
EXO Biologics● Active	0732.982.379
ExoXpert● Active	1003.807.666
Hirundo Biosciences● Active	0681.855.065
HolyFox Invest● Active	1010.693.181
Hyloris● Active	0669.738.676
Hyloris Pharmaceuticals● Active	0674.494.151
Hyloris Therapeutics● Active	1025.029.385
LEGIAPARK● Active	0728.589.170
MAN & SCIENCE● Active	0837.403.770
ONCORADIOMICS● Active	0662.719.440

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	07/07/2026	04/07/2025	15/11/2024	11/07/2023	12/07/2022	06/07/2021
General meeting	30/06/2026	10/06/2025	14/11/2024	13/06/2023	14/06/2022	08/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

14 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/06/2026	07/07/2026	French	PDF
Abridged model	31/12/2024	10/06/2025	04/07/2025	French	PDF
Abridged model	31/12/2023	14/11/2024	15/11/2024	French	PDF
Abridged model	31/12/2022	13/06/2023	11/07/2023	French	PDF
Abridged model	31/12/2021	14/06/2022	12/07/2022	French	PDF
Abridged model	31/12/2020	08/06/2021	06/07/2021	French	PDF
Abridged modelCorrection	31/12/2019	08/06/2020	06/07/2021	French	PDF
Abridged model	31/12/2019	08/06/2020	30/07/2020	French	PDF
Abridged modelCorrection	31/12/2018	08/06/2020	30/07/2020	French	PDF
Abridged model	31/12/2018	12/08/2019	26/08/2019	French	PDF
Abridged model	31/12/2017	10/08/2018	31/08/2018	French	PDF
Abridged model	31/12/2016	13/06/2017	29/09/2017	French	PDF
Abridged model	31/12/2015	14/06/2016	31/08/2016	French	PDF
Abridged model	31/12/2014	09/06/2015	31/08/2015	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 10 M€ and 25 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 14 ended

Active mandates

Jacobsen Management

Director · since 20 avril 2020 · until 09 juin 2026 · 0736.534.955

Represented by Thomas Jacobsen

Active

SVR Management

Managing director · since 20 avril 2020 · until 09 juin 2026 · 0552.806.859

Represented by Van Rompay Stijn

Active

Ended mandates

Jacobsen Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0736.534.955

Ended

SVR Management

Director · since 20 avril 2020 · until 14 juin 2020 · 0552.806.859

Represented by Stijn Van Rompay

Ended

SVR Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Van Rompay Stijn

Ended

SVR Management

Managing director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Van Rompay Stijn

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates26/09/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates05/03/2025
DEMISSIONS, NOMINATIONS
PDF
Capital / shares25/02/2025
CAPITAL, ACTIONS
PDF
Mandates19/05/2023
DEMISSIONS, NOMINATIONS
PDF
Registered office22/09/2022
SIEGE SOCIAL - CAPITAL, ACTIONS
PDF
Registered office07/09/2022
SIEGE SOCIAL
PDF
Capital / shares28/12/2021
CAPITAL, ACTIONS
PDF
Capital / shares28/10/2020
CAPITAL, ACTIONS
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025-5,3 M €↑
2024
Annual accounts 2024-5,8 M €↑
2023
Annual accounts 2023-10,9 M €↓
2022
Annual accounts 2022-9,6 M €↓
2021
Annual accounts 2021-2,6 M €↑
2020
Annual accounts 2020-2,9 M €↑
2019
Annual accounts 2019-4,1 M €↓
2018
Annual accounts 2018-327,6 k €↑
2017
Annual accounts 2017-523,4 k €↓
2016
Annual accounts 2016-389,6 k €↓
2016
Name changeHyloris Developments
2015
Annual accounts 2015-116,4 k €↑
2014
Annual accounts 2014-168,7 k €
2014
Name changeHyloris Pharmaceuticals
05/12/2013
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

Hyloris Developments

Overview

What does Hyloris Developments do?

Trend over 12 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline